PMID- 17164714
OWN - NLM
STAT- MEDLINE
DCOM- 20070308
LR  - 20231213
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 82
IP  - 11
DP  - 2006 Dec 15
TI  - Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host 
      disease and transplant-related mortality in HLA-matched sibling hematopoietic 
      stem cell transplantation.
PG  - 1436-40
AB  - BACKGROUND: The posttransplant period following hematopoietic stem cell 
      transplantation (HSCT) is potentially high risk for developing 
      survival-compromising complications, many of which are known to be under the 
      control of immunogenetic factors. Given the dual role of human leukocyte antigen 
      (HLA)-E molecules in innate and adaptive immune processes, we analyzed the impact 
      of HLA-E polymorphism in genoidentical HSCT setting. METHODS: We analyzed 187 
      HLA-genoidentical sibling pairs for HLA-E polymorphism. To explore its potential 
      association with the incidence of acute and chronic graft versus host disease 
      (aGVHD, cGVHD), severe infections, risk for transplant-related mortality (TRM), 
      and overall survival, HLA-E locus was genotyped by a polymerase 
      chain-reaction-sequence-specific primer (PCR-SSP) strategy. RESULTS: Multivariate 
      analysis, taking into account the patient-, donor- and transplant-related 
      factors, showed that the incidence of aGVHD and TRM at day 180 were low when the 
      genotype was HLA-E*0103/E*0103, either in the donor or in the recipient, the 
      pairs being identical for HLA-E alleles (hazard ratio [HR]=0.71, P=0.009; and 
      HR=0.42, P=0.04, respectively). We also found a trend towards association between 
      E*0103 homozygosity and improved survival (P=0.05). There was no association 
      between HLA-E polymorphism and incidence of severe infections. CONCLUSIONS: These 
      data suggest that the homozygous state for HLA-E*0103 allele behaves as a 
      protective genetic factor against aGVHD and TRM and likely contributes to 
      improved survival in HLA-genoidentical bone marrow transplantation.
FAU - Tamouza, Ryad
AU  - Tamouza R
AD  - Assistance publique- Hopitaux de Paris/Groupement Hospitalier et Universitaire 
      Nord, Institut Universitaire d'Hematologie, et Institut National de la Sante et 
      de la Recherche Medicale U662, Hopital Saint-Louis, Paris, France. 
      tamouza@histo.chu-stlouis.fr
FAU - Busson, Marc
AU  - Busson M
FAU - Rocha, Vanderson
AU  - Rocha V
FAU - Fortier, Catherine
AU  - Fortier C
FAU - Haddad, Yacine
AU  - Haddad Y
FAU - Brun, Manuel
AU  - Brun M
FAU - Boukouaci, Wahid
AU  - Boukouaci W
FAU - Bleux, Helene
AU  - Bleux H
FAU - Socie, Gerard
AU  - Socie G
FAU - Krishnamoorthy, Rajagopal
AU  - Krishnamoorthy R
FAU - Toubert, Antoine
AU  - Toubert A
FAU - Gluckman, Eliane
AU  - Gluckman E
FAU - Charron, Dominique
AU  - Charron D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Genotype
MH  - Graft vs Host Disease/*genetics/*mortality
MH  - HLA Antigens/*genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Antigens Class I
MH  - *Homozygote
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Siblings
MH  - HLA-E Antigens
EDAT- 2006/12/14 09:00
MHDA- 2007/03/09 09:00
CRDT- 2006/12/14 09:00
PHST- 2006/12/14 09:00 [pubmed]
PHST- 2007/03/09 09:00 [medline]
PHST- 2006/12/14 09:00 [entrez]
AID - 00007890-200612150-00012 [pii]
AID - 10.1097/01.tp.0000244598.92049.dd [doi]
PST - ppublish
SO  - Transplantation. 2006 Dec 15;82(11):1436-40. doi: 
      10.1097/01.tp.0000244598.92049.dd.